Vivos 2021 recap: first equine IsoPet therapy, FDA pre-sub for RadioGel IDE, production improved 3x

VIVOS INC

University of Missouri performed first equine IsoPet therapy; excellent outcome confirmed after monitoring.
Pre-submission meeting with FDA for RadioGel IDE; used rapid breakthrough review; revised IDE to be submitted after biocompatibility tests.
Polymer production time reduced and output increased by factor of three; contaminants reduced below FDA guidelines.
New provisional patent filed covering improved hydrogel, other isotopes, and anti-circumvention techniques.
Capital structure in excellent shape: no toxic debt or derivatives; all SEC filings timely.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.